EMBO Molecular Medicine

metrics 2024

Pioneering Discoveries for a Healthier Tomorrow

Introduction

EMBO Molecular Medicine, published by WILEY, stands as a premier forum within the field of molecular medicine, advancing scholarly dialogue and research since its launch in 2009. With an impressive impact factor reflected in its Q1 categorization and ranking as the 12th journal in the discipline of Molecular Medicine by Scopus, it serves as a vital resource for researchers, professionals, and students alike. Operating under an Open Access model, EMBO Molecular Medicine ensures that cutting-edge research is freely accessible, fostering greater collaboration and innovation among the global scientific community. Located in the United Kingdom, the journal encompasses a broad scope, featuring high-quality studies that bridge the gaps between basic molecular biology and clinical applications, making significant impacts on health and disease. With a commitment to excellence and a continuously evolving repertoire of research, this journal play a crucial role in shaping the future of biomedical research and therapy.

Metrics 2024

SCIMAGO Journal Rank3.96
Journal Impact Factor9.00
Journal Impact Factor (5 years)11.00
H-Index142
Journal IF Without Self9.00
Eigen Factor0.02
Normal Eigen Factor3.60
Influence3.75
Immediacy Index1.60
Cited Half Life6.20
Citing Half Life7.50
JCI2.19
Total Documents1735
WOS Total Citations12283
SCIMAGO Total Citations37902
SCIMAGO SELF Citations269
Scopus Journal Rank3.96
Cites / Document (2 Years)8.20
Cites / Document (3 Years)8.73
Cites / Document (4 Years)9.00

Metrics History

Rank 2024

Scopus

Molecular Medicine in Biochemistry, Genetics and Molecular Biology
Rank #12/178
Percentile 93.26
Quartile Q1

IF (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 15/189
Percentile 92.30
Quartile Q1

JCI (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 11/189
Percentile 94.18
Quartile Q1

Quartile History

Similar Journals

Cell Reports Medicine

Bridging molecular discoveries and clinical innovations.
Publisher: CELL PRESSISSN: 2666-3791Frequency: 12 issues/year

Cell Reports Medicine, published by Cell Press, represents a pivotal advancement in the open access landscape of biomedical research since its inception in 2020. With a dedicated focus on the intersection of medicine, biochemistry, genetics, and molecular biology, this journal has quickly established itself as a key resource, earning a remarkable Q1 ranking in these fields. Based in the United States, Cell Reports Medicine boasts impressive metrics, ranking #25 out of 636 in General Medicine and #18 out of 221 in Biochemistry, underscoring its influence and reach within the scientific community, with a notable 96th and 92nd percentile respectively. As a fully open access journal, it fosters global dissemination of knowledge, ensuring that groundbreaking research is readily available to researchers, professionals, and students alike. The journal not only promotes high-quality research but also aims to bridge the gap between molecular discoveries and clinical applications, making it an essential addition to any academic library or researcher's toolkit.

IN VIVO

Elevating biochemistry and molecular biology to new heights.
Publisher: INT INST ANTICANCER RESEARCHISSN: 0258-851XFrequency: 6 issues/year

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.

MOLECULAR PHARMACOLOGY

Elevating Understanding of Molecular Drug Actions
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0026-895XFrequency: 12 issues/year

MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

Journal of Translational Medicine

Unlocking the Future of Translational Medicine.
Publisher: BMCISSN: Frequency: 1 issue/year

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

FASEB BioAdvances

Exploring Breakthroughs in Biological Research
Publisher: WILEYISSN: Frequency: 12 issues/year

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

Annual Review of Pathology-Mechanisms of Disease

Advancing Insights in Pathology and Disease Mechanisms
Publisher: ANNUAL REVIEWSISSN: 1553-4006Frequency: 1 issue/year

Annual Review of Pathology: Mechanisms of Disease is a premier scholarly journal published by ANNUAL REVIEWS that systematically reviews significant advancements in the field of pathology and the mechanisms underpinning various diseases. With an ISSN of 1553-4006 and an E-ISSN of 1553-4014, the journal has established its importance within the academic community, evidenced by its prestigious Q1 rankings in several categories including medicine, pathology, forensic medicine, and plant science for 2023. Notably, it ranks #1 out of 208 in the pathology and forensic medicine category, placing it in the 99th percentile according to Scopus metrics. Although not an open-access journal, it offers crucial insights to researchers, professionals, and students alike by providing a comprehensive understanding of pathophysiological concepts and emerging trends. The journal continues to be an essential resource for those dedicated to advancing research and practical applications in disease mechanisms.

Disease Models & Mechanisms

Exploring Mechanisms Behind Disease Dynamics
Publisher: COMPANY BIOLOGISTS LTDISSN: 1754-8403Frequency: 12 issues/year

Disease Models & Mechanisms is a distinguished peer-reviewed journal dedicated to elucidating the complex interplay of biological processes involved in disease through innovative modeling and mechanistic insight. Published by COMPANY BIOLOGISTS LTD in the United Kingdom, this Open Access journal has been committed to disseminating critical research since 2011, ensuring that valuable findings are accessible to a global audience. With an impressive impact factor and ranked in the Q1 category in fields such as Biochemistry, Genetics, and Molecular Biology, Immunology, Microbiology, Medicine, and Neuroscience, it stands out for its high-quality publications that significantly contribute to the scientific community. The journal encourages submissions that explore the latest breakthroughs in disease modeling and mechanisms, fostering a collaborative environment among researchers, professionals, and students alike. Readers can benefit from state-of-the-art studies covering a spectrum of diseases, providing insights that pave the way for innovative therapeutic strategies.

JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Empowering Researchers with Open Access Knowledge
Publisher: WILEYISSN: 1582-1838Frequency: 12 issues/year

Journal of Cellular and Molecular Medicine, published by Wiley, stands at the forefront of research excellence in the fields of cell biology and molecular medicine. With an impressive impact factor reflected in its 2023 Q2 category ranking for both Cell Biology and Molecular Medicine, this journal provides a vital platform for researchers and professionals alike, fostering innovative findings and groundbreaking discoveries since its inception in 2000. Maintaining an open access policy since 2012, the journal ensures that knowledge is freely disseminated, promoting collaboration and progress across the scientific community. With robust rankings in the Scopus database, including a position within the top 85th percentile in Molecular Medicine, the journal remains committed to advancing understanding of cellular functions and their implications in health and disease. Researchers, professionals, and students will find a treasure of high-quality articles and reviews that not only catalyze academic dialogue but also contribute significantly to practical applications in the life sciences.

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY

Shaping the Future of Experimental Pathology
Publisher: WILEYISSN: 0959-9673Frequency: 6 issues/year

INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, published by Wiley, is a leading peer-reviewed journal dedicated to the field of experimental pathology. With an ISSN of 0959-9673 and E-ISSN 1365-2613, the journal has been a vital resource for researchers and professionals since its inception in 1990, covering a broad spectrum of topics within pathology, cell biology, and molecular biology. The journal's relevancy is underscored by its Q2 ranking in Pathology and Forensic Medicine and Q3 rankings in both Cell Biology and Molecular Biology, as of 2023, reflecting its significant contribution to the scientific community. Although it does not currently offer open access options, readers can benefit from its insightful research articles and reviews that guide advancements in diagnostic pathology and therapeutic strategies. As the journal continues to evolve, it remains committed to facilitating the exchange of innovative ideas and findings that drive progress in experimental pathology and related fields, making it an indispensable platform for scientists, clinicians, and students alike.

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Transforming Understanding through Molecular Biology
Publisher: ELSEVIERISSN: 0925-4439Frequency: 12 issues/year

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, published by Elsevier, is a pivotal journal in the fields of Molecular Biology and Molecular Medicine, recognized for its high impact factor and robust ranking within Scopus categories, holding prestigious quartiles in Q1 for both disciplines as of 2023. With ISSN 0925-4439 and E-ISSN 1879-260X, this journal fosters cutting-edge research from 1990 to 2025, addressing the critical molecular mechanisms underlying human diseases. Its wide-ranging scope includes original research articles, reviews, and advanced theoretical insights, serving as an essential resource for researchers, clinicians, and students alike. The journal is based in the Netherlands, at RADARWEG 29, 1043 NX AMSTERDAM, and while it does not currently offer an open-access option, it continues to maintain a strong presence in the scientific community, enhancing our understanding of molecular processes in health and disease.